The trial of a Mississippi man who claims to have contracted bladder cancer while taking the type 2 diabetes drug Actos is set to go to trial early next year.
Jack Cooper, of Mississippi, claims he acquired bladder cancer while taking the popular diabetes drug. He is one of thousands who have made this claim but will be the first to have the case go to a trial. According to a news update from the national law firm of Parker Waichman LLP, Judge Kenneth R. Freeman has scheduled that trial to begin on Feb. 19. The case will be heard before Freeman in Superior Court of California, County of Los Angeles.
The outcome of this trial will weigh heavily for the thousands of other Americans who claim that taking Actos in the treatment of their type 2 diabetes resulted in them acquiring life-threatening cases of bladder cancer. Parker Waichman, in a news release, cites a recent report in Business Week magazine that indicates as many as 10,000 people may be making similar claims in courts across the country.
Many of those thousands of lawsuits have already been consolidated as part of a Multidistrict Litigation case in U.S. District Court for the Western District of Louisiana before the Honorable Rebecca Doherty. The founding partner at Parker Waichman LLP, Jerrold Parker, has been appointed to the Plaintiffs’ Steering Committee in the MDL. That role places him in a leadership position, especially during the early phases of the MDL, when decisions on evidence and witnesses are made that directly impact future trials and settlements.
The evidence against Actos, and its maker Takeda Pharmaceuticals, appears to be mounting against the safety of the drug. Last June, the Food and Drug Administration warned that taking Actos in the treatment of type 2 diabetes for more than a year significantly increased the risk a person faced of developing bladder cancer.
Actos has become the leading type 2 diabetes medication, taking over that role from the previous leader, Avandia, after it was removed from the market because of its link to dangerous and life-threatening side effects. The sale of Actos has been halted in several European countries after reports linked it to the bladder cancer side effect.
Recent reports on studies conducted for the Journal for the National Cancer Institute established a link between the drug and bladder cancer. A study this summer published in the Canadian Medical Journal Association found that taking Actos increased a person’s chance of developing bladder cancer by 22 percent.
Parker Waichman continues to represent prospective clients in the Actos MDL as those proceedings head closer to trial.